| Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies M Egger, M May, G Chêne, AN Phillips, B Ledergerber, F Dabis, ... The Lancet 360 (9327), 119-129, 2002 | 2128 | 2002 |
| Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study A Sáez-Cirión, C Bacchus, L Hocqueloux, V Avettand-Fenoel, I Girault, ... PLoS pathogens 9 (3), e1003211, 2013 | 1184 | 2013 |
| Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies JA Sterne, M May, D Costagliola, F De Wolf, AN Phillips, R Harris, ... Lancet 373 (9672), 1352, 2009 | 1031 | 2009 |
| Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover JR Almeida, DA Price, L Papagno, ZA Arkoub, D Sauce, E Bornstein, ... The Journal of experimental medicine 204 (10), 2473-2485, 2007 | 901 | 2007 |
| Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men M Mary-Krause, L Cotte, A Simon, M Partisani, D Costagliola, ... Aids 17 (17), 2479-2486, 2003 | 675 | 2003 |
| Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study M Guiguet, F Boué, J Cadranel, JM Lang, E Rosenthal, D Costagliola Lancet oncology 10 (12), 1152-1159, 2009 | 668 | 2009 |
| The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals HIVC Collaboration, M Ray, R Logan, JA Sterne, S Hernandez-Diaz, ... AIDS (London, England) 24 (1), 123, 2010 | 576 | 2010 |
| Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy S Grabar, VL Moing, C Goujard, C Leport, MD Kazatchkine, D Costagliola, ... Annals of internal medicine 133 (6), 401-410, 2000 | 564 | 2000 |
| Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management AMJ Wensing, DA Van De Vijver, G Angarano, B Åsjö, C Balotta, E Boeri, ... The Journal of infectious diseases 192 (6), 958-966, 2005 | 559 | 2005 |
| Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of … C Lewden, D Salmon, P Morlat, S Bévilacqua, E Jougla, F Bonnet, ... International journal of epidemiology 34 (1), 121-130, 2005 | 503 | 2005 |
| Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol D Salmon-Ceron, C Lewden, P Morlat, S Bévilacqua, E Jougla, F Bonnet, ... Journal of hepatology 42 (6), 799-805, 2005 | 472 | 2005 |
| Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy C Besson, A Goubar, J Gabarre, W Rozenbaum, G Pialoux, FP Châtelet, ... Blood, The Journal of the American Society of Hematology 98 (8), 2339-2344, 2001 | 472 | 2001 |
| Polylactic acid implants (New-Fill)® to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA MA Valantin, C Aubron-Olivier, J Ghosn, E Laglenne, M Pauchard, ... Aids 17 (17), 2471-2477, 2003 | 464 | 2003 |
| Changes in causes of death among adults infected by HIV between 2000 and 2005: The “Mortalite 2000 and 2005” surveys (ANRS EN19 and Mortavic) C Lewden, T May, E Rosenthal, C Burty, F Bonnet, D Costagliola, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 48 (5), 590-598, 2008 | 456 | 2008 |
| Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. M May, JA Sterne, C Sabin, D Costagliola, AC Justice, R Thiebaut, J Gill, ... AIDS (London, England) 21 (9), 1185-1197, 2007 | 434 | 2007 |
| Incidence of non–AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus–infected patients M Herida, M Mary-Krause, R Kaphan, J Cadranel, I Poizot-Martin, ... Journal of Clinical Oncology 21 (18), 3447-3453, 2003 | 426 | 2003 |
| Beyond viral suppression of HIV–the new quality of life frontier JV Lazarus, K Safreed-Harmon, SE Barton, D Costagliola, N Dedes, ... BMC medicine 14, 1-5, 2016 | 415 | 2016 |
| Rapid progression to AIDS in HIV+ individuals with a structural variant of the chemokine receptor CX3CR1 S Faure, L Meyer, D Costagliola, C Vaneensberghe, E Genin, B Autran, ... Science 287 (5461), 2274-2277, 2000 | 406 | 2000 |
| Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study … A Mocroft, JD Lundgren, ML Sabin, AA Monforte, N Brockmeyer, ... PLoS medicine 10 (9), e1001510, 2013 | 401 | 2013 |
| Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled … F Ader, M Bouscambert-Duchamp, M Hites, N Peiffer-Smadja, J Poissy, ... The Lancet infectious diseases 22 (2), 209-221, 2022 | 388 | 2022 |
Fabrice BonnetBordeauxVerified email at chu-bordeaux.fr
